Back to Trades
Total Value
$14.5M
Net $10.8M sold
Filing Date
Jul 23, 2026
2 transactions
Sales
$10.8M
2 transactions
Trade Summary
On Jul 21, 2026, ROBINS HARLAN S, Chief Scientific Officer, sold $14.5M of Adaptive Biotechnologies Corp (ADPT) across 2 transactions. The filing covers Common Stock and reflects net selling of $10.8M. Reported prices ranged from $6.55 to $22.12. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Adaptive Biotechnologies Corp
- Ticker Symbol
- ADPT
- CIK
- 0001478320
Insider Information
- Name
- ROBINS HARLAN S
- Role
- Chief Scientific Officer
- Location
- SEATTLE, WA
Filing Details
- Filing Date
- Jul 23, 2026
- Transaction Date
- Jul 21, 2026
- Accession Number
- 0001780851-26-000017
- Form Type
- 4
- Net Trading Amount
- -$10.8M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 21, 2026 | Common Stock | 284,800 | $6.55 | Exercise | $1.9M |
| Jul 21, 2026 | Common Stock | 278,698 | $21.72 | Sale | $6.1M |
| Jul 21, 2026 | Common Stock | 213,702 | $22.12 | Sale | $4.7M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 21, 2026 | ADPT derivative | 284,800 | $6.55 | Exercise | $1.9M |
Want live alerts when ROBINS HARLAN S trades again?
Download Insider Trades to track ADPT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
- (F2)The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- (F3)The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- (F4)The option was fully vested and exercisable.